Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fortunato Morabito

Showing results (171-180 of 302) with videos related to

Pageof 31
Sort By:
Oncology Reports|March 17, 2009
Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphomaPaolo G Gobbi, Francesco Valentino, Marco Danova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2003
Treatment of indolent B-Cell nonfollicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei LinfomiLuca Baldini, Maura Brugiatelli, Stefano Luminari, et al.
British Journal of Haematology|March 29, 2026
Exploiting ALK inhibition in anaplastic large cell lymphoma: Biological rationale and therapeutic integrationSantino Caserta, Enrica Antonia Martino, Mamdouh Skafi, et al.
Leukemia & Lymphoma|April 11, 2003
Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: results of a prospective, multicenter study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL)Marco Lombardo, Fortunato Morabito, Francesco Merli, et al.
Cancers|July 13, 2024
Characteristics and Outcomes of Colorectal Cancer Patients Cared for by the Multidisciplinary Team in the Reggio Emilia Province, ItalyLucia Mangone, Francesco Marinelli, Isabella Bisceglia, et al.
European Journal of Haematology|April 20, 2026
From Time-Limited Therapy to Treatment-Free Observation: The Evolving Role of MRD in CLL ManagementEnrica Antonia Martino, Santino Caserta, Ernesto Vigna, et al.
Cytotherapy|July 20, 2015
Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patientsMassimo Martino, Anna Grazia Recchia, Tiziana Moscato, et al.
Annals of Hematology|May 4, 2026
High-dose ruxolitinib (25 mg twice daily) in myelofibrosis: feasibility, safety, and long-term treatment exposure in a real-world cohortFrancesco Mendicino, Giulio Caridà, Antonella Bruzzese, et al.
European Journal of Haematology|July 9, 2026
Bridging Randomized Trial Efficacy and Real-World Effectiveness in Multiple Myeloma: Integrating Clinical Trials and Real-World Evidence for Individualized CareEnrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, et al.
European Journal of Haematology|April 15, 2026
First-Line Treatment of IGHV-Unmutated Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Targeted and Chemoimmunotherapy RegimensSantino Caserta, Enrica Antonia Martino, Danilo Lofaro, et al.
Pageof 31

Showing results (171-180 of 302) with videos related to

Sort By:
Pageof 31
Oncology Reports|March 17, 2009
Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphomaPaolo G Gobbi, Francesco Valentino, Marco Danova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2003
Treatment of indolent B-Cell nonfollicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei LinfomiLuca Baldini, Maura Brugiatelli, Stefano Luminari, et al.
British Journal of Haematology|March 29, 2026
Exploiting ALK inhibition in anaplastic large cell lymphoma: Biological rationale and therapeutic integrationSantino Caserta, Enrica Antonia Martino, Mamdouh Skafi, et al.
Leukemia & Lymphoma|April 11, 2003
Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: results of a prospective, multicenter study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL)Marco Lombardo, Fortunato Morabito, Francesco Merli, et al.
Cancers|July 13, 2024
Characteristics and Outcomes of Colorectal Cancer Patients Cared for by the Multidisciplinary Team in the Reggio Emilia Province, ItalyLucia Mangone, Francesco Marinelli, Isabella Bisceglia, et al.
European Journal of Haematology|April 20, 2026
From Time-Limited Therapy to Treatment-Free Observation: The Evolving Role of MRD in CLL ManagementEnrica Antonia Martino, Santino Caserta, Ernesto Vigna, et al.
Cytotherapy|July 20, 2015
Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patientsMassimo Martino, Anna Grazia Recchia, Tiziana Moscato, et al.
Annals of Hematology|May 4, 2026
High-dose ruxolitinib (25 mg twice daily) in myelofibrosis: feasibility, safety, and long-term treatment exposure in a real-world cohortFrancesco Mendicino, Giulio Caridà, Antonella Bruzzese, et al.
European Journal of Haematology|July 9, 2026
Bridging Randomized Trial Efficacy and Real-World Effectiveness in Multiple Myeloma: Integrating Clinical Trials and Real-World Evidence for Individualized CareEnrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, et al.
European Journal of Haematology|April 15, 2026
First-Line Treatment of IGHV-Unmutated Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Targeted and Chemoimmunotherapy RegimensSantino Caserta, Enrica Antonia Martino, Danilo Lofaro, et al.
Pageof 31